Non-Current Assets
Long-term marketable securities
Moderna Long-term marketable securities decreased by 3.6% to $2.25B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.9%, from $2.42B to $2.25B. Over 5 years (FY 2020 to FY 2025), Long-term marketable securities shows an upward trend with a 29.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2017
Last reportedQ1 2026May 1, 2026
How to read this metric
An increase indicates a long-term capital preservation strategy, while a decrease suggests the liquidation of long-term investments to fund operations or debt repayment.
Detailed definition
This represents long-term investments in debt securities that the company intends to hold for more than one year. These...
Peer comparison
Used by mature companies with strong cash flows to manage long-term liquidity and investment returns.
Metric ID:
non_current_assets_available_for_sale_securities_debt_se_908f76Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.21B | $6.44B | $6.84B | $9.17B | $10.16B | $8.66B | $8.32B | $7.44B | $6.11B | $5.27B | $4.68B | $3.64B | $2.33B | $2.34B | $2.49B | $2.42B | $2.37B | $2.14B | $2.34B | $2.25B |
| QoQ Change | — | +53.1% | +6.2% | +34.0% | +10.8% | -14.8% | -3.9% | -10.5% | -18.0% | -13.6% | -11.3% | -22.2% | -36.1% | +0.4% | +6.8% | -3.0% | -1.8% | -9.7% | +9.0% | -3.6% |
| YoY Change | — | — | — | — | +141.5% | +34.4% | +21.6% | -18.9% | -39.9% | -39.1% | -43.8% | -51.1% | -61.9% | -55.7% | -46.7% | -33.5% | +2.1% | -8.2% | -6.3% | -6.9% |
Range$2.14B – $10.16B
CAGR-12.3%
Avg YoY Growth-13.3%
Median YoY Growth-26.2%
Long-term marketable securities at Other Companies
Frequently Asked Questions
- What is Moderna's long-term marketable securities?
- Moderna (MRNA) reported long-term marketable securities of $2.25B in Q1 2026.
- How has Moderna's long-term marketable securities changed year-over-year?
- Moderna's long-term marketable securities decreased by 6.9% year-over-year, from $2.42B to $2.25B.
- What is the long-term trend for Moderna's long-term marketable securities?
- Over 5 years (2020 to 2025), Moderna's long-term marketable securities has grown at a 29.6% compound annual growth rate (CAGR), from $639.00M to $2.34B.
- What does long-term marketable securities mean?
- Long-term investments in debt securities held for interest income.